Double-Blind, Double-Dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients.

Trial Profile

Double-Blind, Double-Dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2017

At a glance

  • Drugs Budesonide (Primary) ; Mesalazine (Primary)
  • Indications Crohn's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Dr Falk Pharma
  • Most Recent Events

    • 15 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top